Skip to main content
. 2015 Aug 17;35(18):3189–3199. doi: 10.1128/MCB.00196-15

FIG 5.

FIG 5

MLL1 regulates IL-6 expression and H3K4me3 levels at the IL-6 promoter. (A) IL-6 and IκBα expression upon combined knockdown of ARTD1 and either SET7 or MLL1 in NIH 3T3 cells after 4 h of LPS stimulation (n = 3). The rightmost panels show the knockdown efficiency of siRNA treatment against SET7 and MLL1 by qPCR analysis. (B, left) IL-6 expression upon combined knockdown of ARTD1 and KDM5B in NIH 3T3 cells after 4 h of LPS stimulation (n = 1). (Right) Knockdown efficiency of siRNA treatment against KDM5B by qPCR analysis. (C) H3K4me3 occupancy at the IL-6 and IκBα promoters upon knockdown of ARTD1 and either SET7 or MLL1 in NIH 3T3 cells after 4 h of LPS stimulation (n = 3). The data are presented as means ± the SD and were analyzed by one-way ANOVA, followed by Bonferroni's post hoc test. *, P < 0.05. (D) H3K4me3 occupancy at the IL-6 and IκBα promoters upon combined knockdown of ARTD1 and either SET7 or MLL1 in NIH 3T3 cells after 4 h of LPS stimulation (n = 3). (E) MLL1 and p65 coimmunoprecipitation in HEK293T cells overexpressing MLL1 (lanes 1 and 4, unstimulated; lane 2, 1 h of PMA; lane 3, 4 h of PMA).